FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT).

#1128

Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.

Aim(s): Investigated the role of FDG PET as a prognostic factor P-NET treated with Lu-PRRT.

Materials and methods: A total of 65 G1-G2 P-NET patients (pts), with documented radiological progression, were treated with 2 different activities of 18.5 GBq or 27.8 GBq according to the pts’s kidney function and bone marrow reserve. 31 received a total activity (TA) of 27.8 GBq and 34 a TA of 18.5GBq. TA was divided into 5 cycles, 6-8 weeks apart. 56 of 65 pts underwent a FDG PET before Lu-PRRT.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Sansovini M

Authors: Sansovini M, Stefano S, Ianniello A, Nicolini S, Fantini L,

Keywords: PRRT, neuroendocrine, FDG-PET,